The medical device industry looks to 113th Congress for some sort of reprieve from the medical device tax. MassDevice.com looks at what battles are left.
It's a question the medtech industry faces now that what was perhaps its best opportunity to repeal the medical device tax faded when Congress passed a stop-gap measure staving of the so-called fiscal cliff without addressing the levy.
As medical device companies begin paying those first tax bills due on January 15th, MassDevice.com takes a look at the next fights to come on the medical device tax.
Medical device industry lobbying group AdvaMed issued a statement Wednesday morning promising to continue the fight to repeal the device tax, but it's not clear where the battle will take. The med tech industry needs an appropriate legislative vehicle on which some sort of repeal effort could be a part of, and that vehicle was meant to be the fiscal cliff deal.
The good news is that the next chance may come soon.
At the end of February the federal government will need to extend the nation's $16.4 trillion borrowing limit and stave off automatic cuts to both domestic and military programs. The threat of a potential default of the nation's credit, combined with the desire to mitigate deep cuts will likely spur another round of negotiations.
The GOP will likely still be smarting from its inability to get any real spending cuts on the table during the fiscal cliff negotiations, so the debt ceiling may be the best chance for another run at a grand bargain and a revival of the medical device tax repeal fight. Recent history suggests, however, that grand bargains aren't part of Washington's play book anymore.
Will the 113th Congress be lucky for the medical device industry?
The fiscal cliff was the swan song of the 112th congress, widely considered one of the most ineffective and divided legislative bodies in generations. What will the 113th congress look like in terms of the medical device industry?
Hologic hands former Stryker CEO Steven MacMillan the keys to the corner office, agrees to take on 2...
Cyberonics plans to buy back an additional 1 million shares before the end of fiscal 2015.
Ventana, a Roche Group subsidiary, won 510(k) clearance from the Food & Drug Administration for...
TYRX touts expanded 510(k) clearance for its AIGISRx N antibacterial envelope, now cleared for use...
Wall Street analysts find opportunities for savvy investors looking to take advantage of the fallout...